Overview

Rituximab and Carmustine, Cytarabine, Etoposide, and Melphalan Followed By Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as carmustine, cytarabine, etoposide, and melphalan, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab and combination chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination chemotherapy followed by autologous hematopoietic stem cell transplantation in treating patients who have B-cell non-Hodgkin's lymphoma.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Nebraska
Collaborator:
National Cancer Institute (NCI)
Treatments:
Carmustine
Cytarabine
Etoposide
Etoposide phosphate
Melphalan
Rituximab
Criteria
DISEASE CHARACTERISTICS:

- Diagnosis of non-Hodgkin's lymphoma

- Any B cell

- CD20-positive disease

- Failed prior primary induction therapy

- Meets 1 of the following criteria:

- Chemotherapy-refractory disease

- Received at least 3 prior chemotherapy regimens

- Mantle cell lymphoma

- Eligible for transplantation

- No history of T-cell lymphoma

PATIENT CHARACTERISTICS:

Age

- 19 and over

Performance status

- WHO 0-2

Life expectancy

- At least 6 months

Hematopoietic

- Absolute neutrophil count ≥ 1,000/mm^3*

- Platelet count > 50,000/mm^3*

- Hemoglobin > 9.0 g/dL* NOTE: *Unless due to lymphomatous involvement of the bone
marrow

Hepatic

- Not specified

Renal

- Not specified

Other

- Not pregnant or nursing

- Fertile patients must use 2 methods of effective contraception

- No other concurrent serious disease or condition that would preclude study
participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- See Disease Characteristics

Endocrine therapy

- Not specified

Radiotherapy

- Not specified

Surgery

- Not specified